Company profile for Amicus Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Amicus Therapeutics, Inc. (Nasdaq:FOLD) is a global biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases. We have a robust development pipeline of treatments for a range of human genetic diseases. Our lead product candidate, migalastat, is a personalized medicine in late-stage development to treat individuals with Fabry disease on the basis of their genetic di...
Amicus Therapeutics, Inc. (Nasdaq:FOLD) is a global biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases. We have a robust development pipeline of treatments for a range of human genetic diseases. Our lead product candidate, migalastat, is a personalized medicine in late-stage development to treat individuals with Fabry disease on the basis of their genetic diagnosis. Our lead biologics program is AT-GAA, a uniquely engineered Pompe disease ERT that will be administered in combination with a pharmacological chaperone.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1 Cedar Brook Drive Cranbury, NJ 08512
Telephone
Telephone
+1 609-662-2000
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/31/3178217/15991/en/Amicus-Therapeutics-to-Present-at-Upcoming-Investor-Conferences-in-November-2025.html

GLOBENEWSWIRE
31 Oct 2025

https://www.globenewswire.com/news-release/2025/10/23/3171888/15991/en/Amicus-Therapeutics-to-Announce-Third-Quarter-2025-Financial-Results-on-November-4-2025.html

GLOBENEWSWIRE
23 Oct 2025

https://www.globenewswire.com/news-release/2025/09/08/3146157/15991/en/New-4-Year-Data-for-Pombiliti-cipaglucosidase-alfa-atga-Opfolda-miglustat-Presented-at-ICIEM.html

GLOBENEWSWIRE
08 Sep 2025

https://www.globenewswire.com/news-release/2025/08/29/3141407/15991/en/Amicus-Therapeutics-to-Present-at-Upcoming-Investor-Conferences-in-September-2025.html

GLOBENEWSWIRE
29 Aug 2025

https://www.prnewswire.com/news-releases/clinical-progress-in-rare-disease-signals-long-term-revenue-potential-for-innovators-302523131.html

PR NEWSWIRE
07 Aug 2025

https://www.globenewswire.com/news-release/2025/07/31/3124831/15991/en/Amicus-Therapeutics-Announces-Second-Quarter-2025-Financial-Results-and-Corporate-Updates.html

GLOBENEWSWIRE
31 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty